Purpose: Although MET exon 14 ( MET ex14)-altered lung cancers were first identified more than a decade and a half ago, the frequency of CNS metastatic disease remains poorly defined. Furthermore, the seminal trial of crizotinib in these patients (PROFILE 1001) did not report patterns of CNS response or progression., Patients and Methods: Patients with pathologically confirmed, advanced non-small-cell lung cancers (NSCLC) harboring a MET ex14 alteration by targeted DNA/RNA sequencing were studied. The incidence of brain metastases and the outcomes of MET inhibition with crizotinib were analyzed., Results: Eighty-three patients with MET ex14-altered metastatic NSCLC were identified. The incidence of CNS metastases at diagnosis was 17% (95% CI, 10% to 27%). The lifetime incidence was 36% (95% CI, 26% to 47%); 83% of patients had parenchymal disease, and 17% had leptomeningeal disease. The probability of having brain metastasis at 1, 2, and 3 years was 24%, 35%, and 38%, respectively. Fifty-four patients received crizotinib. The median time to radiologic CNS progression was 5.8 months (range, 3.7-20.0 months). Patterns of crizotinib progression were as follows: intracranial only in 10% of patients, intracranial and extracranial in 12%, and extracranial only in 78%. In patients with brain metastases before treatment, the median time on crizotinib was 7.5 months (range, 7.2-11.7 months)., Conclusion: CNS metastases, including leptomeningeal disease, occurred in more than a third of patients with MET ex14-altered lung cancers. In crizotinib-treated patients with or without CNS metastases, CNS failure was seen in less than a quarter of patients on progression., Competing Interests: The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Michael OffinHonoraria: OncLive Consulting or Advisory Role: PharmaMar, Novartis, Targeted Oncology Travel, Accommodations, Expenses: Bristol Myers Squibb, Merck Sharp & DohmeJia LuoHonoraria: Targeted OncologyJordan DienstagStock and Other Ownership Interests: AbbVie, Bristol Myers Squibb, Thermo Fisher Scientific, AllerganCharles M. RudinConsulting or Advisory Role: AbbVie, Harpoon Therapeutics, Genentech, AstraZeneca, Ascentage Pharma, Bicycle Therapeutics, Celgene, Daiichi Sankyo, Ipsen, Loxo, PharmaMar, Bridge Medicines, Amgen, Jansen, Syros Pharmaceuticals Research Funding: AbbVie/Stemcentrx (Inst), Viralytics (Inst), Merck (Inst), Daiichi Sankyo (Inst), Genentech (Inst)Gregory RielyResearch Funding: Novartis (Inst), Genentech (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Infinity Pharmaceuticals (Inst), Mirati Therapeutics (Inst), Merck (Inst), Takeda (Inst) Patents, Royalties, Other Intellectual Property: Patent application submitted covering pulsatile use of erlotinib to treat or prevent brain metastases (Inst) Travel, Accommodations, Expenses: Merck Sharp & Dohme Other Relationship: Pfizer, Genentech, TakedaNatasha RekhtmanHonoraria: Physicians’ Education ResourceMaria E. ArcilaHonoraria: Invivoscribe, Biocartis Consulting or Advisory Role: AstraZeneca Travel, Accommodations, Expenses: AstraZeneca, Invivoscribe, Raindance TechnologiesGlenn HellerResearch Funding: Janssen DiagnosticsMarc LadanyiConsulting or Advisory Role: Bristol Myers Squibb, Bayer Research Funding: Loxo (Inst), Helsinn Therapeutics, Merus NV (Inst), Elevation Oncology (Inst)Bob T. LiConsulting or Advisory Role: Guardant Health, Hengrui Therapeutics, Eli Lilly (Inst), Genentech (Inst) Research Funding: AstraZeneca (Inst), GRAIL (Inst), Daiichi Sankyo (Inst), Hengrui Therapeutics (Inst), Guardant Health (Inst), Amgen (Inst), Eli Lilly (Inst), MORE Health (Inst) Patents, Royalties, Other Intellectual Property: US62/514,661 (Inst), US62/685,057 (Inst)Mark G. KrisConsulting or Advisory Role: AstraZeneca, Regeneron, Pfizer, Daiichi Sankyo Travel, Accommodations, Expenses: AstraZeneca, Pfizer Other Relationship: Memorial Sloan Kettering Cancer Center, Genentech Open Payments Link: https://openpaymentsdata.cms.gov/physician/markgkris/summaryPaul PaikHonoraria: Celgene, Takeda, Calithera Biosciences, Boehringer Ingelheim, EMD Serono, AstraZeneca Consulting or Advisory Role: Celgene, EMD Serono, Takeda, Calithera Biosciences, AstraZeneca, Boehringer Ingelheim Research Funding: Celgene, EMD Serono Travel, Accommodations, Expenses: EMD SeronoAlexander DrilonHonoraria: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, MORE Health, Research to Practice, Foundation Medicine, Peerview Consulting or Advisory Role: Ignyta, Loxo, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Genentech, Helsinn Therapeutics, BeiGene, Hengrui Therapeutics, Exelixis, Bayer, Tyra Biosciences, Verastem, Takeda/Ariad/Millennium, BerGenBio, MORE Health, Eli Lilly, Verastem, AbbVie, 14ner/Elevation Oncology, Remedica, Archer Biosciences, Monopteros Research Funding: Foundation Medicine Patents, Royalties, Other Intellectual Property: Wolters Kluwer (royalties for Pocket Oncology) Other Relationship: Merck, GlaxoSmithKline, Teva, Taiho Pharmaceutical, Pfizer, PharmaMar, Puma Biotechnology No other potential conflicts of interest were reported., (© 2020 by American Society of Clinical Oncology.)